Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany.
Klinik Bad Trissl GmbH, Bad-Trissl-Straße 73, 83080 Oberaudorf, Germany.
Breast. 2019 Apr;44:81-89. doi: 10.1016/j.breast.2018.12.008. Epub 2018 Dec 20.
In breast cancer, large tumor size, positive nodal stage and a triple-negative tumor subtype are associated with reduced survival, but the interactions between these prognostic factors are not well understood.
Here we re-evaluated the impact of tumor size, nodal stage and tumor subtype on disease-free survival (DFS), overall survival (OS), distant disease-free survival (DDFS) and breast cancer specific survival (BCSS) in a retrospective analysis using data from the adjuvant SUCCESS A trial. Subgroup analyses were conducted to assess whether the effect of tumor size and nodal stage on survival depended on tumor subtype.
Increasing tumor size, higher nodal stage and triple negative breast cancer (TNBC) were associated with unfavorable prognosis (all p < 0.001). There was no significant interaction between tumor subtype and tumor size (p > 0.5 for all four survival endpoints), but we found significant interactions between tumor subtype and nodal stage (p < 0.05 for all four survival endpoints), with no differences in survival among tumor subtypes for patients with pN0 tumors (all p > 0.05) and pronounced differences in survival among tumor subtypes for patients with positive nodal stage (all p < 0.001).
This analysis confirms tumor size, nodal stage and tumor subtype as independent prognostic factors in high-risk early breast cancer. Nodal-positive patients with TNBC had a considerably worse outcome compared to nodal-positive patients with another tumor subtype. This underlines the importance for early detection particularly for patients with TNBC.
EudraCT 2005-000490-21; ClinicalTrials.gov Identifier: NCT02181101.
在乳腺癌中,肿瘤体积大、淋巴结阳性和三阴性肿瘤亚型与生存率降低相关,但这些预后因素之间的相互作用尚不清楚。
在这里,我们使用辅助 SUCCESS A 试验的数据进行回顾性分析,重新评估了肿瘤大小、淋巴结分期和肿瘤亚型对无病生存(DFS)、总生存(OS)、远处无病生存(DDFS)和乳腺癌特异性生存(BCSS)的影响。进行了亚组分析,以评估肿瘤大小和淋巴结分期对生存的影响是否取决于肿瘤亚型。
肿瘤体积增大、淋巴结分期升高和三阴性乳腺癌(TNBC)与预后不良相关(均 p<0.001)。肿瘤亚型和肿瘤大小之间没有显著的相互作用(所有四个生存终点的 p>0.5),但我们发现肿瘤亚型和淋巴结分期之间存在显著的相互作用(所有四个生存终点的 p<0.05),对于 pN0 肿瘤患者,肿瘤亚型之间的生存无差异(均 p>0.05),而对于淋巴结阳性患者,肿瘤亚型之间的生存差异显著(均 p<0.001)。
这项分析证实了肿瘤大小、淋巴结分期和肿瘤亚型是高危早期乳腺癌的独立预后因素。与淋巴结阳性的其他肿瘤亚型患者相比,淋巴结阳性的 TNBC 患者的预后明显较差。这强调了早期检测的重要性,特别是对于 TNBC 患者。
EudraCT 2005-000490-21;ClinicalTrials.gov 标识符:NCT02181101。